Why 10x Genomics Doubters Were Wrong Before A 485% Gain

If you only skimmed 10x Genomics headlines about falling revenue, a swing from a US$34.5 million profit in Q2 2025 to a US$17.9 million loss in Q2 2026, and removal from Russell value indexes, you might have expected a punishing year for holders. For 10x Genomics shareholders, the return over the past year was 484.9%, including dividends. If you had been deciding whether to buy on 27 October 2025, what did the record really signal about that kind of payoff versus the clear funding and profitability risks?

10x Genomics is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Two Stories 10x Genomics Investors Had To Weigh

The shares cost US$13.59 at the start of the period, so anyone looking at 10x Genomics then had to decide which story felt more realistic.

The bullish view pointed to a Fair Value of US$15.08, essentially the price implied if modest 2.2% annual revenue growth and a shift from losses toward a 14.2% profit margin played out over roughly three years.

The bearish side saw a Fair Value of US$9, tied to an assumption that revenue would decline 0.9% a year and that prolonged US research funding cuts could keep earnings under pressure.

What The Results Changed For 10x Genomics

The launch and early shipments of the Atera spatial biology platform gave fresh support to the bullish story that product breadth could matter more than short term funding strain. The hard Q2 2026 numbers pulled the other way. Revenue slipped from US$172.9 million to US$151.0 million and net income moved from a US$34.5 million profit to a US$17.9 million loss, so the profitability piece of the optimistic case stayed unproven. Overall, the evidence cut both ways.

The key question was whether new platforms could offset pressure on earnings quality. When you assess another tools maker, track that same link between product launches and reported net margin rather than assuming new hardware or software will quickly repair profits.

What Today’s 10x Genomics Price Already Assumes

Today 10x Genomics trades at US$78.02. The selected Narrative’s Fair Value sits below that level, reflecting a view that recent enthusiasm for Atera, spatial biology and AI linked workflows may already be heavily reflected in the quote.

For a buyer at today’s price, the core bet is that Atera driven spatial demand and AI backed consumables volume hold up. The question is how the risk of prolonged funding strain and slower instrument recovery weighs on that assumption.

"The numbers imply that the share price already embeds strong confidence in Atera driven spatial growth, AI linked demand for complex experiments, and progress toward clinical applications, which leaves limited room for disappointment if any of these drivers underperform."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Looking One Step Beyond 10x Genomics

10x Genomics points toward cutting edge tools for complex disease questions. The same customers still need treatments, not just richer datasets.

One large healthcare group is pouring resources into drug discovery and device development. It spreads that spending across many established platforms instead of chasing a single blockbuster.

Its researchers target difficult conditions where existing options leave meaningful gaps. Hospitals using advanced genomic analysis may also seek therapies matching those insights.

As more complex diagnostics reach the clinic, demand for these treatments may shift. The scale and breadth of that pipeline start to look like the real story.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 19% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com